Great North Pharmacy Research Collaborative Conference 2021 Technology: the great pharmacy enabler



Academic Health Science Network North East and North Cumbria

Friday July 9, 2021, 1pm

SPEAKERS

Dr Wasim Baqir

National Pharmacy Advisor: Pharmacy Integration Programme / Primary Care, Community Services and Strategy Directorate/ NHS England and Improvement

Professor Graham Evans

Chief Information and Technology Officer/SIRO, North Tees and Hartlepool NHS Foundation Trust /Chief Digital Officer NENC, Integrated Care System/ Honorary Professor, Teesside University

Dr Jane Brown

Pharmacy Dean, Health Education England

Gemma Donovan

Academic Practitioner in Pharmacy Practice, School of Pharmacy, Pharmaceutical and Cosmetic Sciences, University of Sunderland

Laura Stavert

Advanced Pharmacist Practitioner, Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust

Calum Polwart

Specialist Cancer Pharmacist, South Tees Hospitals NHS Foundation Trust

Richard Brown Chief Officer, Avon LPC



Great North Pharmacy Research Collaborative 4th Annual Regional Conference Technology: the great pharmacy enabler

9 July 2021 1:15pm – 5pm

@GtNorthPharmRes #GNPRC2021

In association with:





Welcome

Dr Wasim Baqir

National Pharmacy Advisor: Pharmacy Integration Programme Primary Care, Community Services and Strategy Directorate NHS England and Improvement

In memory of





Lesley Davidson


Dr Alan Worsley

Housekeeping

- Please ensure microphones are muted.
- If you have any questions throughout the session then please use the chat facility. We will attempt to address questions, if we can't then we will follow up after the event.
- View the posters in the breaks <u>https://bit.ly/GNPRC9Jul2021</u>
- Speaker presentations will be circulated following the event.
- The event will be recorded and shared.
- Some presentations are pre-recorded, please be aware of varying volume levels during the event.
- Join the conversation on social media #GNPRC2021
- Event Information: https://bit.ly/GNPRC9Jul2021



Thank you to our speakers





Pre-Registration Presentations



Investigating the Effects of COVID-19 on High INR Readings

Megan Blenkinship Pre-Registration Pharmacist South Tyneside and Sunderland NHS Foundation Trust



Investigating the Effects of COVID-19 on High INR Readings

By Megan Blenkinship

Great North Pharmacy Research Collaborative; 4th Annual Regional Conference: Technology: the great pharmacy enabler; 9th July 2021 1pm – 5pm – Online @GtNorthPharmRes #gnpharmconf21



Background



- The anticoagulant medicine warfarin, is widely used and requires patients to have INR monitoring at Warfarin Clinics at least every 12 weeks (NICE, 2020).
- The adverse effects of warfarin include haemorrhage at high INR readings.
- A patient's response to warfarin is affected by many factors including diet, lifestyle, other medications and co-morbidities.
- On the 23rd March 2020, the UK entered a lockdown period due to the Covid-19 pandemic, which has been proposed to affect INR readings, either from infection of the virus or from the impact of the pandemic including (Speed et al., 2020) (NHS, 2020).



Aims and Objectives



<u>Aim</u>: To investigate the relationship between the incidence of high INR readings \geq 8 and Covid-19.

Objectives:

- Identify how many patients had INR readings ≥8 between March 23rd 2020 and 5th January 2021.
- Identify how many patients were positive for Covid-19 when they had INR readings ≥8.
- To determine whether INR readings ≥8 are more prevalent in specific patient groups during Covid-19.
- To determine what factors have affected patients INR readings during the Covid-19 pandemic.

Method



- All Warfarin Clinic patients and domiciliary visits, who had INR readings ≥8 during the study dates were included.
- Patients were identified using the report function on the anticoagulation clinic recording system: INR star.
- Each INR Star and Meditech patient profile was accessed for data collection.
- Data collection included:
 - The patient's INR reading, age, gender, warfarin indication, target INR, ethnicity, any Covid-19 test results, diet changes, medication changes, lifestyle changes and changes in patient co-morbidities.




Results **33 Patients Number of Patients Positive for Covid-19:** Three White British **Most Common** Warfarin Indication: 15 Male **Atrial Fibrillation** Most 18 Female Common INR Target: 2.5

Thirty-three patients aged between 28 and 91 years old, who all had an ethnicity of White British were investigated in the study.



Results



- Additional factors affecting INR readings, included;
 - Illnesses or infections
 - Medication changes
 - Lifestyle changes
 - Diet changes
 - > Warfarin dose changes.
- Three patients had no known reason for their high INR reading.
- The most common medication changes were the prescribing of antibiotics, analgesia and changes in warfarin dosing.

Age and Increased INR Readings

- Over half of the patients in the study were aged 70 years old or older.
- Studies show that anticoagulation control in warfarin patients is poorest in the elderly population (Goudie et al., 2004) (Abohelaika et al., 2016).
- Pharmacokinetic changes in the elderly population may also affect INR readings (Khoury & Sheikh, 2014).
- A patient's age is not affected by Covid-19, thus, there is no evidence that INR readings are raised due to the pandemic.

Covid-19 Infection and Increased INR Readings

- A recent study found 53% of patients with an INR reading >8 had a confirmed or suspected Covid-19 infection (Speed et al., 2020).
- Some researchers have proposed that Covid-19 may increase the risk of thrombosis (Ranucci, et al., 2020) and that liver impairment is not a prominent feature of Covid-19 (Zhang et al., 2020).
- Only 3 patients with an INR reading ≥8 had a positive Covid-19 test, thus it is not possible to associate the two factors together.

Gender and Increased INR readings

- Over half of the patients investigated in the study were female, however it was not significantly higher than the number of male patients.
- Research has found that Covid-19 disproportionately affects more men than women with regards to fatalities, with 54.3% of all deaths involving Covid-19 being male (Office for National Statistics, 2021).
- The number of positive Covid-19 cases in the study was not significant, thus, no link could be determined in the study.

Ethnicity and Increased INR Readings

- A recent government review suggests Black and Ethnic minorities are more at risk of Covid-19, with death rates twice as high in Bangladeshi communities and up to 50% higher among other ethnic groups compared with White British people (Patel et al., 2020).
- As 100% of the study population were White British, no separate analysis by race or ethnicity was carried out.



Alcohol Consumption and Increased INR Readings

- Three patients changed their alcohol consumption during the pandemic.
- For some patients, who only consume alcohol at social occasions, the closure of the hospitality industry meant this could no longer occur and Government restrictions on alcohol sales in shops and pubs, may have contributed to this (Morris, 2020).
- Differently, there has been a significant increase in alcohol sales during the pandemic (Ellison, 2020).
- Lifestyle changes can happen at anytime and cannot be explicitly attributed to the Covid-19 pandemic unless documentation on INR star specified this.

Diet Changes and Increased INR Readings

- Seven patients in the study had diet changes that they attributed to the pandemic.
- A reduction in food consumption due to stockpiling (Bachelor, 2020) or reduced weekly supermarket visits, to comply with restrictions may have affected this (GOV.UK, 2021).
- Moreover, reduced vitamin K levels have also been reported in patients with Covid-19 (Dofferhoff, et al., 2020) (Speed et al., 2020).
- Both weight loss and malnutrition can also increase warfarin sensitivity (Mueller et al., 2014).

Medication Changes and Illness leading to Increased INR Readings

- Eleven patients had new medical conditions leading to medication changes, mostly due to antibiotics.
- 81% of patients with possible or confirmed Covid-19 were prescribed antibiotics (Speed et al., 2020).
- Four patients had changes to their analgesia, attributed to paracetamol, which may have increased warfarin sensitivity (Hylek et al., 1998).
- It is not possible to associate these changes to the pandemic, unless the changes are due to a positive Covid-19 test result.

Dose Changes and Incorrect Doses leading to Increased INR Readings

- Four patients had taken an incorrect warfarin dose prior to their high INR reading.
- Dose confusion amongst study participants was common.
- A common cause of warfarin adverse effects is poor treatment adherence, due to a lack of patient understanding about their treatment and education from healthcare professionals (European Society of Cardiology, 2016).
- Prolonged INR monitoring due to the pandemic restrictions, may have led to patients taking incorrect doses for a longer period of time.

Conclusion and Recommendations

The study results provide no conclusive evidence that raised INR readings are due to the Covid-19 pandemic. As current research is limited, further studies are needed to determine an association between the high INR readings and Covid-19.



INR/PT monitoring could be carried out in all Covid-19 positive patients, not just warfarin patients to assess the risk of haemorrhagic events and to get a larger sample size with different ethnicities.



Local results could be compared to the rest of the UK and the amount of high INR readings can be compared to the same time period the previous year when the UK was not in the pandemic.



Pharmacists must continue to confirm warfarin doses and Warfarin Clinic details, allowing patients to notify clinics of any changes to their medications, lifestyle or medical conditions. Therefore, healthcare professionals can assess the need for more frequent INR monitoring.



Thank You For Listening!



References

- Abohelaika, S., Wynne, H., Avery, P., Robinson, B., Kesteven, P., & Kamali, F. (2016). Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management. *British Journal of Clinical Pharmacology*, 82(4), 1076-1083.
- Bachelor, L (2020) MPs in plea to government over UK's Covid-19 stockpiling. The Guardian. Available from https://www.theguardian.com/world/2020/mar/21/mps-plea-government-uk-covid-19-stockpiling-coronavirus [accessed 04 March 2021].
- Dofferhoff, A., Piscaer, I., Schurgers, L., Visser, M., van den Ouweland, J., de Jong, P., . . . Janssen, R. (2020). Reduced vitamin K status as a potentially modifiable risk factor of severe COVID-19. *Clinical Infectious Diseases*, 1-8. Available from https://watermark.silverchair.com/ciaa1258.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAArQwggKwBgkqhkiG9w0 BBwagggKhMIICnQIBADCCApYGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMAUwbhjtawmaK6qFAAgEQgIICZzLs-UJgNh42GQWwcfpRcIfd9Xnhrm4OAjnDvq5Svk6pwz [accessed 04 March 2021].
- Ellison, A. (2020). Coronavirus: Bingeing Britons buy 20% more alcohol for lockdown. The Times. Available from https://www.thetimes.co.uk/article/coronavirus-bingeing-britons-buy-20-per-cent-more-alcohol-for-lockdown-njh6jn55q [accessed 04 March 2021].
- European Society of Cardiology. (2016). Poor patient warfarin knowledge may increase risk of deadly side effects. Science Daily. Available from https://www.sciencedaily.com/releases/2016/04/160415092437.htm [accessed 04 March 2021].
- Goudie, B., Donnan, P., Fairfield, G., Al-Agilly, S., & Cachia, P. (2004). Dependency rather than old age increases the risk of warfarin-related bleeding. *British Journal of General Practice, 54*, 690-692.
- GOV.UK. (2021). National lockdown: Stay at Home Guidance. GOV.UK. Available from https://www.gov.uk/guidance/national-lockdown-stay-at-home [accessed 04 March 2021].
- HM Government. (2020). Race Disparity Unit. Quarterly report on progress to address covid-19 health inequalities. GOV.UK. Available from https://www.gov.uk/government/organisations/race-disparity-unit [accessed 03 March 2021].
- Hylek, E., Heiman, H., Skates, S., Sheehan, M., & Singer, D. (1998). Acetaminophen and other risk factors for excessive warfarin anticoagulation. *JAMA*, 279(9), 657–662.
- Janssen, R., Visser, M., Dofferhoff, A., Vermeer, C., Janssens, W., & Walk, J. (2020). Vitamin K metabolism as the potential missing link between lung damage and thromboembolism in Coronavirus disease 2019. *The British Journal of Nutrition*, 1-8. Available from https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/vitamin-k-metabolism-as-the-potential-missing-link-between-lung-damageand-thromboembolism-in-coronavirus-disease-2019/C3E7267D0D19B048E1D8AB9D83754CFC [accessed 01 March 2021].
- Khoury, G., & Sheikh-Taha, M. (2014). Effect of age and sex on warfarin dosing. *Clinical Pharmacology Advances and Applications, 6*, 103-106. Accessed from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103915/pdf/cpaa-6-103.pdf.
- Morris, J. (2020). COVID-19 and alcohol: an enduring effect on home drinking habits? Society for the Study of Addiction. Available from https://www.addiction-ssa.org/covid-19-and-alcohol-an-enduring-effect-on-home-drinking-habits/ [accessed 04 March 2021].

References

- Mueller, J., Patel, T., Halawa, A., Dumitrascu, A., & Dawson, N. (2014). Warfarin Dosing and Body Mass Index. Annals of Pharmacotherapy, 48(5), 584-588.
- NHS England and NHS Improvement. (2020). *Clinical guide for the management of anticoagulant services during the coronavirus pandemic.* NICE. Available from https://www.nice.org.uk/Media/Default/About/COVID-19/Specialty-guides/specialty-guide-anticoagulant-services-and-coronavirus.pdf [accessed 03 February 2021].
- NICE Excellence (2020) Oral Anticoagulants | Treatment Summary |. BNF NICE. [online] bnf.nice.org.uk. Available at: https://bnf.nice.org.uk/treatment-summary/oral-anticoagulants.html [Accessed 11 September 2020].
- Office for National Statitics. (2021). Deaths registered weekly in England and Wales, provisional: week ending 19 February 2021. Office for National Statistics. Available from

https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredweeklyinenglandandwalesprovis ional/weekending19february2021 [accessed 04 March 2021].

- Patel, P., Hiam, L., Sowemimo, A., Devakumar, D., & McKee, M. (2020). Ethnicity and Covid-19. *British Medical Journal* (2282), 369. Available from https://www.bmj.com/content/bmj/369/bmj.m2282.full.pdf [accessed 03 March 2021].
- Ranucci, M., Ballotta, A., Di Dedda, U., Bayshnikova, E., Dei Poli, M., Resta, M., . . . Menicanti, L. (2020). The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. *Journal of Thrombosis and Haemostasis, 18*(7), 1747-1751. Available from https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14854 [accessed 04 March 2021].
- Speed, V., Patel, R.K., Byrne, R., Roberts, L.N., & Arya, R. A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic. *Thrombosis research*. 2020; 192:73–74.
- WHO. (2021). *Coronavirus disease (COVID-19) advice for the public*. World Health Organization. Available from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public [accessed 01 March 2021].
- Williams, H. (2020). Guidance for the safe switching of Warfarin to Direct Oral Anticoagulants for Patients with Non-Valvular AF and Venous Thromboembolism (PE/DVT) during the Coronavirus Pandemic. Royal Pharmaceutical Society. Available from https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Coronavirus/FINAL%20Guidance%20on%20safe%20switching %20of%20warfarin%20to%20DOAC%20COVID-19%20Mar%202020.pdf?ver=2020-03-26-180945-627 [accessed 01 March 2021].
- Zhang, Y., Zheng, L., Liu, L., Zhao, M., & Xiao, J. (2020). Liver impairment in COVID-19 patients: A retrospective study analysis of 115 cases from a single centre in Wuhan city, China. *Liver International, 40*(9), 2095-2102. Available from https://onlinelibrary.wiley.com/doi/full/10.1111/liv.14455 [accessed 01 March 2021].





An Audit Assessing the Appropriateness of Controlled Drug Destruction and its Relevant Documentation


Aidan Bowler Pre-Registration Pharmacist North Tees and Hartlepool NHS Foundation Trust





An Audit Assessing the Appropriateness of Controlled Drug Destruction and its Relevant Documentation

Aidan Bowler



Excellence as our Standard

Collaborative Aspirational Respectful Empathetic





Background

June 2015 – NHS sponsored study estimated £300 Million

of prescribed medicines were wasted a year

Our trust saves roughly £10,000 from non-controlled drugs returns within a 6-week period

So what about controlled drugs (CD's)?





Aims and Objectives

Standards were produced from the trusts SOP's

1) Each CD drug intended for destruction must be recorded into the CD destruction register.

2) CD medication should be returned into stock (not destroyed) unless it meets ANY of the criteria listed below:

- Patient's own drugs
- <6 months expiry
- In poor condition
- Part of a blister pack
- Cut foil strips

- Issued >6 months ago
- Loose tablets
- Opened liquids
- More medication than quoted on the container/box





Method

All data was collected over a 6-week period


Records of all CD drug returns stored for destruction in pharmacy were assessed to see whether they had been written in the destruction register according to the Trust policy, they were also assessed against the criteria for returning in standard 2

The drug cost was analysed based on pricing listed on the dispensing software ascribe






Results



7.3% of CD's for destruction were not recorded in the destruction book.



22.9% of the drugs could have been returned rather than destroyed.

$\pm 60.32 + \pm 80.52 + \pm 178.36 = \pm 319.20$

Cost of CD's that could have been returned Price of doop kits Cost of labor

Total cost

£782.08

Total cost of all drugs destroyed





Conclusion

Limitations with high cost drugs and reduced hospital admissions due to COVID including high risk patients

So what could be changed to improve compliance for returns?

- Implementing more education around the topic of waste management and assessing CD returns
- Reviewing the policy
- Having a returns checklist on the CD cupboard door to improve adherence to the standards
- Help from technicians with returns
- Reviewing overprescribing of CD's themselves



Evaluating the Quality of Patient Follow-Up Post-Myocardial Infarction: An Audit of ACE inhibitor/ARB and Beta-Blocker Up-Titration in Primary Care

Caitlyn Madden Pre-Registration Pharmacist Northumbria Healthcare NHS Foundation Trust



Northumbria Healthcare

NHS Foundation Trust

Evaluating the Quality of Patient Follow-Up Post-Myocardial Infarction: An Audit of ACE inhibitor/ARB and Beta-Blocker Up-Titration in Primary Care C.Madden, P.Davies



Background

 ~1.4 million people alive in the UK today have survived a myocardial infarction (MI) (1). Results

- Cost of acute MI ~£4200 and acute heart failure (HF) exacerbation ~£3000 (2).
- NICE guidelines: An angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) and a beta-blocker (BB) post-MI titrated to the maximum tolerated dose (3,4).
- Optimal doses (≥50%) shown to reduce mortality, morbidity and hospitalisation rates compared to suboptimal doses (<50%) (5–7).
- NICE standard maximum dose ACEi/ARB and BB to be achieved within 6 and 11 weeks of discharge, respectively.

Methodology

- Project setting: GP practice (patient population 19,000)
- Clinical system search conducted for patients coded with an acute MI in the previous 12 months.
- Data extracted from patient records to determine titration history.

Audit standard: Maximum dose ACE inhibitor/ARB and beta-blocker to be achieved within 6 and 11 weeks of discharge, respectively

- 26 patients identified, 23 (88%) of which were eligible for and prescribed ACEi/ARB and BB therapy at discharge. Only 3 (12%) and 2 (8%) patients were at maximum doses of ACEi/ARB and BB, respectively.
- Of those not discharged on maximum doses, no patients achieved maximum doses of either ACEi/ARB or BB within 6 and 11 weeks, respectively. All patients failed to meet the audit standard.
- A HF nurse followed up 3 (12%) patients who all achieved maximum doses of ACEi/ARB and an increase in BB by 6 months.



🗖 yes 📕 no

Fig 1. Percentage of patients who received at least one attempted increase in their ACEi/ARB or BB dose 3 months and 6 months post-discharge. Excludes patients discharged on maximum doses.




Fig 2. Mean percentage of maximum BNF dose ACEi/ARB and BB patient's were prescribed at discharge and at 3 and 6 months post-discharge. Excludes those discharged at maximum doses.




Fig 3. Percentage of patient on maximum BNF doses of ACEi/ARB and BB at discharge and 3 months and 6 months post-discharge. Includes those discharged on maximum doses.

Discussion

- Appeared that patient's followed up by a HF nurse up were more likely to have their treatment optimised compared to those who were not; potentially causing differing hospitalisation and mortality rates
- Below average compared to previous research where on average between 46%-48% of the maximum dose of ACE inhibitor/ARB and between 34%-41% of the maximum dose of beta-blocker were achieved after 3 months (7).

Conclusion

Up-titration of ACEi/ARB and BB in patient's post-MI was below the UK average reported in previous research. The average dose patient's received 6 months post-MI was below optimal doses shown to reduce hospitalisation and mortality rates. None of the patient's met the audit standard – no one received maximum dose ACEi/ARB and BB therapy within 6 and 11 weeks of discharge, respectively. Patient's followed up by HF nurses appeared to receive more intense therapy quicker. A quality improvement project is being established to develop processes to identify patients and support healthcare professionals with up titration.

References

1. British Heart Foundation. UK Circulatory Diseases Factsheet. Br Hear Found. 2021;(March):1–21. 2. Danese MD, Gleeson M, Kutikova L, et al. Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. BMJ Open 2016;6:e011805. doi:10.1136/bmjopen-2016-011805

- 3. Recommendations | Acute coronary syndromes | Guidance | NICE National Institute of Clinical Excellence. 2020
- 4. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200m.
- Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical Effectiveness of Beta-Blockers in Heart Failure. Findings From the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry. J Am Coll Cardiol [Internet]. 2009;53(2):184–92.
 Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure left-ventricular dysfunction: A systematic overview of data from individual patients. Lance 2000;355(1925):1575–81.

7. Ouwerkerk W, Voors AA, Anker SD, et al. Determinants and clinical outcome of uptitration of Einhibitors and beta-blockers in patients with heart failure: A prospective European study. Eur Heart J. 2017;38(24):1883–90.



An Assessment of the Electronic Documentation of Medicine Reconciliation

Sabrina Mahmoud Pre-Registration Pharmacist North Tees and Hartlepool NHS Foundation Trust






An Assessment of the Electronic Documentation of Medicine Reconciliation



By Sabrina Mahmoud



Excellence as our Standard

Collaborative Aspirational Respectful Empathetic

CIAN CHASTLEPOO

BACKGROUND

Medicines reconciliation (MR) on hospital admission aims to reduce the risk of harm due to medication omission or inappropriate prescribing



A medicines optimisation report, published by NICE in 2015, identified a **30-70%** unintentional variance between medications that patients were taking pre and postadmission. [1]

Accurate documentation of MR is crucial and an effective standard operating procedure (SOP) should facilitate this. [2]

Why did I choose this topic?

The Trust changed from paper based MR to electronic MR and approved an SOP to facilitate this change however, since its implementation, there has been no review of its effectiveness




North Tees and Hartlepool

NHS Foundation Trust




OBJECTIVES



Collaborative Aspirational Respectful Empathetic

Excellence as our Standard

<u>METHOD</u>



- 2 different MR records from each adult ward were reviewed daily between 01/02/2021 and 05/02/2021.
- Ethical approval was not required
- case numbers were used to identify patients with complete medicine reconciliation at random
- each was audited by the author.



North Tees and Hartlepool

NHS Foundation Trust




AUDIT STANDARDS

- 1. Pharmacist/technician should speak to the patient when appropriate
- 2. A summary of the final drug history must be recorded
- 3. Discrepancies between the list compiled and drugs prescribed should be documented
- 4. Problems requiring further investigation/intervention should be documented
- 5. Information regarding allergies, sensitives and adverse drug reactions should be documented within the MR
- 6. Pharmacist/technicians should document clearly if the patient receives a NOMAD and details of patients pharmacy should be recorded
- 7. Details of acute medications should be recorded
- 8. Details of care home should be documented when appropriate



RESULTS



Collaborative Aspirational Respectful Empathetic



CONCLUSION

- The SOP states that discrepancies can be communicated either verbally or via documentation in the medical notes. Interestingly it also states that verbal communication is preferred to ensure timely action.
- Clear need to amend the current SOP to clarify necessary elements of MR documentation combined with re-launch followed by re-audit after 6 months.
- Stipulation between desirable and essential documentation criteria is also needed.
- These results are not a reflection of the quality of MR.
- The implementation of electronic recording is relatively new; therefore, the pre-existing SOP requires review and further clarity is required to determine which information must be documented.



Considerations:

- Covid 19
- Winter pressures
- Verbal communication




Collaborative Aspirational Respectful Empathetic



Auditing the Prescribing of Oral Tetracycline's for the Management of Acne in Patients >12 Years Old in a GP Surgery

Hannah McMillan Pre-Registration Pharmacist North Cumbria Integrated Care NHS Foundation Trust



topical treatment with oral antibiotics and re-audit in 12 months.

http://www.pcds.org.uk [Accessed 2/2/21] NICE, Acne vulgaris: CKS, 2020, Online available at: https://cks.nice.org.uk [Accessed 9/3/21]



Q&As with the Pre-Registration Pharmacist Finalists



Comfort Break and Virtual Poster Viewing

https://bit.ly/GNPRC9Jul2021



100

Comfort Break and Virtual Poster Viewing

https://bit.ly/GNPRC9Jul2021



Integrated Medicine in the Digital Age

Professor Graham Evans Chief Information and Technology Officer/SIRO, North Tees and Hartlepool NHS Foundation Trust Chief Digital Officer NENC, Integrated Care System Honorary Professor, Teesside University



North East North Cumbria Integrated Care System

"Integrated Medicine in the Digital Age"

Professor Graham Evans

Chief Digital Officer NENC ICS

Chief Information and Technology Officer North Tees and Hartlepool NHS Foundation Trust



Contact details:

Email: <u>dr.gevans@nhs.net</u>

Telephone: +44 (0) 1642624793

Twitter: @DrGraham



• Context

- NENC ICS Digital Strategy <u>headlines</u>
- Medicine in a digital age spotlight Pharmacy


• Case study


• Questions?



ICS Context – NENC Integrated Care System

North East & North Cumbria








- Largest ICS in England
 - Population of 3.2M
 - 4 X ICP's
- Legacy of collaborative working
 - Regional (NESHA)
 - FT landscape
- Digital is one of 6 ICS priorities
 - Digital Care Programme (DCP)
 - Digital strategy and roadmap
 - CIO Network
 - Flagship Programmes
- Chief Digital Officer (CDO) Role
 - Support DCP SRO
 - Direct NENC ICS Digital Strategy
 - Coordinate delivery






NENC ICS Priority Workstreams

- 1. Improving population health and preventing ill health
- Optimising health services specifically through ensuring high quality standards across all services and delivering safe and sustainable care in the most appropriate setting
- Digital transformation making the best use of technology, data and IT to ensuring efficient and effective services
- 4. Workforce transformation identify how doctors, nurses and other health and care professionals can work across organisations and sites, particularly hospital and community services; support and train staff to work differently; retain our existing workforce and jointly address recruitment challenges.
- 5. Mental health improve access to services and standards of care.
- 6. Learning disabilities improve quality of care, waiting times and outcomes for patients.



Digital strategy approach/format Integrated Care System

North East & North Cumbria



-

considering others and working as a joined up

system to strengthen our capabilities to interact over secure digital infrastructures.

People, Process and Technology.

Free public

We're providing free WiFi in our

public buildings, to help our to help our citizens to stay connected....

WiFi

We've worked together to implement a regional

Cyber Response

Approach, ensuring all organisations follow an appropriate methodology that

focusses equally upon;

Connecting

Learning


What this mean

& The Future

Back State Page 8

ICS Digital strategy approach/format

North East & North Cumbria



ICS Digital Governance review new arrangements in place.

Future-proofed

- ICS Digital Roadmap
- Lots delivered, COVID helped
- More to do future opportunities
- Miniaturisation driven evolution
- Digital by default
- Solid foundations essential
- Regional strategic direction
- Domain & place/ICP delivery plans
- ICP/Place/Organisational alignment



Digital Interactions

Consultations ٠

- Digital first access to primary care
- 'Digital models' to reduce outpatients *
- Video consultations *
- Apps- NHS App- Becomes 'front door' ٠
- Personalisation Self-Care / Remote monitoring * ٠
- * Examples of rapid adoption to COND response - Increased use of apps (diabetes / respiratory / maternity / online therapies)





NHS





Digital Infrastructure



- All trusts fully digitised by 2024
- Standards: info sharing and Cyber security
- Development of shared records (GNCR)





Optimising Health Services - Diagnostics

Digital Pathology












Laboratory Information Management System



Patient Centred







INR Self-Testing Service

Enhancing care for patients on warfarin

Falls Prevention Service A digitally enabled care pathway to help those at risk of falls





NI.

Many other priority digitally enabled health and care programmes evolving



Digital dependency

- Unintended consequences
- ICS Next steps
- ICS Design Framework
- Planning guidance
- Digital is not an option, but a necessity

"Think like a patient, act like a taxpayer"





Sir Simon Stevens 2014









Understand Care System What is the problem we are trying to fix?

North East & North Cumbria

Paper-Based Systems and Records

- Cannot meet the demands of modern healthcare service
 - Present inherent risk for patient safety
 - Introduce costly inefficiencies
 - Provide poor visibility for performance
 - Distance patients from decision making and ownership



- 10% of hospital patients are known suffer an adverse drug error
- 1,200 lives could be saved per year
- Each adverse error can extend patient stays by 8.5 days
- Direct costs to the NHS > £500m
- Significant year on year increase in reported adverse drug errors
- c. 76% attributable to acute care

<u>Sources:</u> A Spoonful of Sugar | Audit Commission (2001) Safety in Doses | NPSA (2009)



- Illegible, ambiguous, incomplete drug charts
- Time wasted locating charts and deciphering information
- Missed / late doses
- Poor and inconsistent allergy recording / checking
- Poor communication between clinicians regarding changes or additional doses (e.g. stat meds)
- Medication charts not re-written in a timely manner




• Poor visibility of performance and outcome data



Me Cher	M. IM		
REGULAR MEDICATIONS	Marine and Cherry Later Competer Marine and Cherry Later Competer Marine Marine Competer Marine Competer		
VARIABLE DOLL REDICATION	44 5× 5/4 3/4 9/4 1/9 1/4		REGULAR MEDICATIONS
The Party Inc. of	Indus	ALCOMOTION TWEET	The second secon
Taxa De La compañía de la	Dose	1 1	the - angener of and and
Annual Spectra State Spectra Spectra			dany -
MARTARIN (Manyuga)(Cournadin) 0052	100		The second second
	Dose		My/to sung war
DOCTOPIE MULT ENTER administration times		BARTANN DUCKTON FREEMO	Your Your Your Your Your Your Your Your
3/4 Fuclordouli m		Print Lingel B	The same to same
the play 19 2rid	4 Star an Pasta M	Divertienen Balt.	The Secon fel
Tomas and Tapping and the and	a grow har the	tain	
3/4 Harris mile www. El	1 10 01 0 1 A		3/4 Internal E C / Da / D a to 10 st
echi and and a second and and and a second and and a second and a se	A A A A A A A A A A A A A A A A A A A	Stationard II mather regar timotory r gase sets there fail	The to roug the
A REAL PROPERTY REAL	20010	Contraction of the second	The second secon
The Manual Protocology	A MARINE THE		100 manue Aller
14 Madepar Be 0	TOR BAL	NAROW FOR ANTEINET ADAMAGED BY COM	19 Agard 10 AL a ROOD Da
of my to the side gter meals	2 Josh CU DAN	tant A tang T	Ny/P semiled
	E AIND ROLL	Notices and D (1)	There spin no when here when the Art 16 - Of 199
1 Pilnayen - El	Justip (b) / Paper my	De Lases (L) Ref averance - ethen superfy ar contant D & generate (N)	Alle Mulaper 19/50.
In song tas	AUV SUGA	Sector Agent	P3 1/4 Lott 1/43
man defining new 2	2 ANEANA	Set spreading (1)	manuffun marine manuffun 17 210 A
Remandial Avia	- 8 - 7 - 7	A DECK	A Nervanitur Noter

Date 12.1- 5	n14.8.								32	156	61	
Time	0610	010	12 30	133		16:30	Time	Insulin	Dose		Ordered By	
Blood Glucose	67	3.3	24.4	200	16:5	10-4	12/1/9	titumen M2	264	5/2	Ac	pruta
Urine Glucose		1		278			12/119	+ HUMMIN		3/6		a
Urine Ketones				NA			1.4117	i naran in r	1 00	3/ 4		Edeur
,	99	-	13/1									<i>e</i> D
Time	1930			0300			Time	Insulin	Dose	Route	Ordered By	
Blood Glucose	8-3	3-1	1.3	5.3	7.5	8.1	15/1/2			se.	0	241
Urine Glucose							1800	Humb my	cu	SIC	30	
Urine Ketones								· · · · · · · · · · · · · · · · · · ·			1 - 2	
Time Blood Glucose				105			Time	Insulin	Dose	Route	Circlaned By	
Date 13/11		1720	22-	-1 -5	-		Time	Insulin	Doen	Boute	Ordered By	Chan B
Blood Glucose	18.0	87	6.3	105							1	-
Urine Glucose				1			1800	Hunste m	- Ma	SE	00	me
Unine Ketones		2		1					631	7.		
141.	•••••								7	,		
Time	105.00	2	1200	1250	17.20		Time	Insulin	Dose	Ploute	Orchand By	Given By
Blood Glucose	1-12	1 8	20.5	19.8	65	-	08.00	Humen Ma	260	SIC	ax.	Barry 1
Urine Glucose				28.7			1600	Humit m	2(46U	SIC	80	Salp
Urine Ketones		1		NEG				-	The			
ate 1.5 . 1 .	99						,		-*	ER	ROR	Shan
Time	-120	220	23 00	00.00	0430	OLIO	Time	Insulin	Dose		Crysprod By	
Blood Glucose		6.1	6.1		3-1	8.4	0800	- Manual MB	30.0	-ste	eary.	-
Urine Glucose				06 00					Liscot			
				10.0	Sector College				LACE COM		1	



'He wrote in a doctor's hand, which from the beginning of time has been so disastrous to the pharmacist and so profitable to the undertaker'

Mark Twain 1835 -1910







Case study - NHS North Tees and Hartlepool NHSFT (NTHFT)

NTHFT have a history for digital medicines innovation, NTHFT where an early adopter to deploy a solution for ward-based pharmacy techs using the software of COWs and to have ward-based pharmacy tech services, a key recommendation from the defining - **Spoonful of Sugar report**.




Integrated Care System North Tees and Hartlepool NHS FT

North East & North Cumbria



ICS North Tees and Hartlepool NHS FT

North East & North Cumbria



Integrated Care System North Tees and Hartlepool NHS FT

North East & North Cumbria



Summary

CUSTOMER

North Tees and Hartlepool NHS Foundation Trust

CHALLENGE

Improve Inefficiencies of paper medication records

OUTCOME

Access to vital prescribing Information in seconds, supported by FBD Multilex medication clinical decision support Joining the dots to improve care -Inside North Tees' adoption of the TrakCare EPMA

North Tees and Hartlepool NHS Foundation Trust

North Tees and Hartlepool NHS Foundation Trust, which employs over 5,600 staff and has a 570-bed capacity, was the first English NHS Trust to deploy the InterSystems' TrakCare electronic patient record, in 2015. Since then, the Trust has been using TrakCare to help it achieve its digital health ambitions. Having built on these firm foundations, the Global Digital Exemplar 'Fast Follower' Trust is starting to realise the multiple clinical and efficiency benefits that come with digital transformation.


The Trust has recently completed the roll out of a new electronic prescribing and medications administration (EPMA) module to all inpatient and emergency wards, marking the next stage in the Trust's ambitious digital journey.

Described by Dr Graham Evans, the Trust's Chief Information and Technology Officer as "one of the biggest transformational changes we will implement as part of our EPR programme," the successful adoption of the EPMA is changing and improving the way clinicians work, cutting red tape and improving outcomes for the 400,000 people who the trust cares for every year. Consultant Physician Dr Jay Vasani and Senior Clinical Matron Claire Ranson describe the impact the new EPMA is having on patients and professionals at one of the UK's most technologically advanced hospitals. Winner is North Tees and Hartlepool NHS Foundation Trust and InterSystems

Best use of EPMA



NHS trust saves its nurses nearly 20,000 hours a year through ePMA hubpublishing.co.uk







'The transformation journey within the hospital is one of evolution, not revolution. Everybody is bought into the idea that we need to digitise a lot of processes, reduce our reliance on paper and improve clinical care.'

Dr Jay Vasani, CCIO Consultant Physician North Tees and Hartlepool NHS Foundation Trust







'Don't do the same things better, do better things......'



Thank you & Questions?





Breakout Session

Once the rooms open you will be automatically moved to your chosen room.

Please be patient as this may take a few minutes due to the number of people on the call

If you didn't select a session you will remain in the main room, you could use this time to view our posters.

We will do our best to get you into the correct room $\ensuremath{\mathfrak{O}}$



Taking the Pharmacy Workforce Forward in a Digital World

Dr Jane Brown Pharmacy Dean Health Education England

Taking the pharmacy workforce forward in a digital world

Dr Jane Brown FRPharmS

Pharmacy Dean – North School of Pharmacy & Medicines Optimisation, Health Education England

www.hee.nhs.uk

The main thing that worries me is technology.....

Mrs K.B. (81 years)

@NHS_HealthEdEng

What do we mean by digital?

- Technology?
- E-prescribing
- Robotic dispensing
- E-transfer of information
- Virtual consultations (phone / video)
- Electronic patient records (with patient access)
- Decision support tools
- Simulation / technology enhanced learning

Digital activity accelerated by the pandemic

- Virtual:
 - Learning
 - Consultations
 - Meetings
 - Conferences
 - Team briefs / away days
- Working from home:
 - Reduced commute
 - Work / life balance
 - Home schooling



- Provide digital services and tools to give people more control over their own health and the care they receive from the NHS
- Give health and care staff the technology they need to help them complete administrative tasks more quickly, freeing up time to spend with patients

Challenges

- Access to IT / clinical systems
- Wifi
- Access to on-line resources
- Use of trusted information resources
- Clunkiness of some systems
- Different techniques required
 - Consultation / communication skills
 - Educator skills
- Loss of personal connections
- Digital literacy / capability


What is digital literacy?

"Digital literacies are those capabilities that fit someone for living, working, learning, participating and thriving in a digital society."

Think about

Health and care workers
Patients / carers / public

Conscious Competence Learning Model



@NHS_HealthEdEng

Health and Care Digital Capabilities Framework

- 1. Communication, collaboration and participation
- 2. Teaching, learning and self-development
- 3. Information, data and content literacies
- 4. Creation, innovation and research
- 5. Technical proficiency
- 6. Digital identity, wellbeing, safety and security

https://www.hee.nhs.uk/sites/default/files/documents/Digital%20Literacy%20Capa bility%20Framework%202018.pdf

CPPE - How digital technology can transform care

- On completion of all aspects of this learning programme you should be able to:
 - describe digital healthcare and how is it relevant to your practice and users of your service
 - recognise how digital technologies can improve patient safety
 - identify the various data sources that can be used to support your practice and enable people to self-manage their long-term conditions
 - discuss how digital technologies can transform and enhance healthcare
 - signpost people to appropriate digital resources to optimise their healthcare

https://www.cppe.ac.uk/programmes/l/digital-e-01

This is about people not computers

@NHS_HealthEdEng



100

Comfort Break and Virtual Poster Viewing

https://bit.ly/GNPRC9Jul2021



Breakout Session

Once the rooms open you will be automatically moved to your chosen room.

Please be patient as this may take a few minutes due to the number of people on the call

If you didn't select a session you will remain in the main room, you could use this time to view our posters.

We will do our best to get you into the correct room $\ensuremath{\mathfrak{O}}$





1st Place: Pre- Registration Poster

Presented by

Anne Henry, Advanced Pharmacist Training Programme Director - North East, and Kay Fenwick, Pre-Registration Pharmacist Training Programme Director – North East Health Education England

1st Place: Pre-Registration Presentation

Presented by Jessica Hardisty, Associate Dean, Pre-Registration Training Health Education England

1st Place: Open Poster Call

Presented by Will Horsley, Pharmacy Lead for Specialised Commissioning NHS England & Improvement





1st Place: Pre-Registration Poster

Presented by Kay Fenwick, Pre-Registration Pharmacist Training Programme Director – North East Health Education England

1st Place

Megan Blenkinship

Investigating the effects of Covid-19 on high INR readings







1st Place: Pre-Registration Presentation

Presented by Jessica Hardisty, Associate Dean, Pre-Registration Training Health Education England

1st Place

Hannah McMillan

Auditing the prescribing of oral tetracycline's for the management of acne in patients >12 years old in a GP surgery








1st Place: Open Poster Call

Presented by Will Horsley, Pharmacy Lead for Specialised Commissioning NHS England & Improvement

1st Place

Rachel Nealen

"Healthy Living Pharmacy' and 'Making Every Contact Count'- what will be the legacy of COVID-19?





Closing Remarks

Dr Wasim Baqir National Pharmacy Advisor: Pharmacy Integration Programme Primary Care, Community Services and Strategy Directorate NHS England and Improvement





Thank you for joining us and have a lovely evening

- Speaker presentations will be circulated following the event.
- The event has been recorded and will be shared.
- A short survey will be circulated, please take a couple of minutes to complete it as your feedback is important to us.
- To be notified of details of next years conference, follow us on Twitter @GtNorthPharmRes

